Implantable contraceptives for women

Human Reproduction Update

Volumn 9, Issue 1, 2003, Pages 49-59

  Meirik, Olav ^a   Fraser, Ian S ^b   d'Arcangues, Catherine ^a   Affandi, Biran ^c   Branche, Vivian ^s   Chikamata, Davy ^a   Croxatto, Horacio ^s   Curtis, Kate ^d   Diaz, Soledad ^s   Dorflinger, Laneta ^e   Edouard, Lindsay ^f   El Mouelhy, Mawaheb Tawhid ^s   Faundes, Anibal ^s   Gabelnick, Henry ^g   Glasier, Anna ^h   Li Hui, Han ⁱ   Hickey, Martha ^j   Huezo, Carlos ^k   Jordan, Alex ^l   Kithinji, Rose ^m   Mekbib, Tekle Ab ⁿ   Miller, Suellen ^o   Ortayli, Nuriye ^p   Peterson, Herbert ^a   Proemono, Ida ^c   Rodgers, Kathleen ^q   Rusdianto, Eka ^c   Shastri, Prasad ^r   Sivin, Irving ^o   more..

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF INDONESIA   (Indonesia)

^d NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^e FAMILY HEALTH INTERNATIONAL   (United States)

^f UNITED NATIONS   (United States)

^g Contraceptive Res/Dev Program ^*  (United States)

^h Family Planning and Well Woman Services   (United Kingdom)

ⁱ Beijing Hospital of Gynaecology and Obstetrics   (China)

^j IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^k Intl Planned Parenthood Federation ^*  (United Kingdom)

^l Center for Drug Evaluation and Research   (United States)

^m KENYATTA NATIONAL HOSPITAL   (Kenya)

ⁿ MARIE STOPES INTERNATIONAL   (United Kingdom)

^o POPULATION COUNCIL   (United States)

^p ISTANBUL UNIVERSITY   (Turkey)

^q UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^r Massachusetts Institute of Technology Cambridge   (United States)

^s Massachusetts Institute of Tech ^*

more..

Author keywords

Contraception; Implant; Progestogen only contraceptive; WHO consensus paper

Indexed keywords

CARBOHYDRATE; CONTRACEPTIVE AGENT; DESOGESTREL; ELCOMETRINE; ETHYLENE VINYL ACETATE COPOLYMER; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; LIPID; NOMEGESTROL ACETATE; POLYMER; PROGESTERONE; SILASTIC; STEROID; THYROID HORMONE; THYROTROPIN; THYROXINE; THYROXINE BINDING GLOBULIN;

ACNE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; BODY WEIGHT DISORDER; BONE DENSITY; BREAST CANCER; BREAST FEEDING; BREAST TENDERNESS; CARCINOGENICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG IMPLANTATION; DRUG INFORMATION; DRUG MANUFACTURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; EVIDENCE BASED MEDICINE; FAMILY PLANNING; FATIGUE; FEMALE; FEMALE CONTRACEPTIVE DEVICE; FEMALE FERTILITY; FETUS MALFORMATION; FOLLICLE CYST; GALLBLADDER DISEASE; GENOTOXICITY; HAIR LOSS; HEADACHE; HEALTH CARE QUALITY; HEALTH PRACTITIONER; HEALTH SERVICE; HEMATOLOGIC DISEASE; HIRSUTISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LIBIDO DISORDER; LIPID METABOLISM; LIVER DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MOOD DISORDER; NAUSEA; PELVIC INFLAMMATORY DISEASE; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; REVIEW; SAFETY; SATISFACTION; SKIN DISEASE; TRAINING; UTERINE CERVIX CANCER; VAGINA BLEEDING; VERTIGO; WORLD HEALTH ORGANIZATION;

CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; COST-BENEFIT ANALYSIS; DRUG IMPLANTS; FEMALE; HUMANS; PATIENT SATISFACTION; WORLD HEALTH ORGANIZATION;

EID: 0037219264     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/dmg004     Document Type: Review

References (94)

1. Affandi, B. (1998) An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. Contraception, 58 (Suppl.), 99S-107S.
2. Affandi, B. (1999) Pregnancy after removal of etonogestrel implant contraceptive (Implanon). Med. J. Indonesia, 8, 62-64.
3. Affandi, B., Prihartono, J., Lubis, F., Sutedi, H. and Samil, R.S. (1987a) Insertion and removal of Norplant contraceptive implants by physicians and nonphysicians in an Indonesian clinic. Stud. Fam. Plann., 18, 302-306.
4. Affandi, B., Santoso, S.S., Djajadilaga, Hadisaputra, W., Moelek, F.A., Prihartono, J., Lubis, F. and Samil, R.S. (1987b) Pregnancy after removal of Norplant implants contraceptive. Contraception, 36, 203-209.
5. Alvarez, F., Brache, V., Faúndes, A., Tejada, A.S. and Thevenin, F. (1996) Ultrasonographic and endocrine evaluation of ovarian function among Norplant® implant users with regular menses. Contraception, 54, 275-279.
6. Alvarez-Sanchez, F., Brache, V., Montes-de-Oca, V., Cochon, L. and Faundes, A. (2000) Prevalence of enlarged ovarian follicles among users of levonorgestrel subdermal contraceptive implants (Norplant). Am. J. Obstet. Gynecol., 182, 535-539.
7. Barbosa, I., Coutinho, E., Athayde, C., Ladipo, O., Olsson, S.E. and Ulmsten, U. (1995) The effects of nomegestrol acetate subdermal implant (Uniplant) on carbohydrate metabolism, serum lipoproteins and on hepatic function in women. Contraception, 52, 111-114.
8. Barnhart, K.T., Furman, I., Pommer, R., Coutinho, E. and Devoto, L. (1997) Changes in the menstrual bleeding of users of a subdermal contraceptive implant of nomegestrol acetate (Uniplant) do not influence sexual frequency, sexual desire, or sexual enjoyment. Fertil. Steril., 67, 244-249.
9. Biswas, A., Viegas, O.A., Coelingh-Bennink, H.J., Korver, T. and Ratnam, S.S. (2001) Implanon® contraceptive implants: effects on carbohydrate metabolism. Contraception, 63, 137-141.
10. Bondurant, S., Ernster, V. and Herdman, R. (eds) (2000) Safety of silicone breast implants. Institute of Medicine, National Academy Press, Washington DC.
11. Bongaarts, J. and Johansson, E. (2000) Future Trends in Contraception in the Developing World: Prevalence and Method Mix. Policy Research Division Working Papers No. 141. Population Council, New York, NY. Available at http://www.popcouncil.org/pdfs/wp/41.pdf.
12. Brache, V., Faúndes, A., Johansson, E. and Alvarez, F. (1985) Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of Norplant® implants. Contraception, 31, 261-273.
13. Brache, V., Massai, R., Mishell, D.R., Moo-Young, A.J., Alvarez, F., Salvatierra, A.M., Cochon, L., Croxatto, H., Robbins, A. and Faúndes, A. (2000) Ovarian function during use of Nestorone subdermal implants. Contraception, 61, 199-204.
14. Brache, V., Faundes, A., Alvarez, F. and Cochon, L. (2002) Non-menstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception, 65, 63-74.
15. Bruce, J. (1987) Users' perspectives on contraceptive technology and delivery systems: highlighting some feminist issues. Technology in Society, 9, 359-383.
16. Buckshee, K., Chatterjee, P., Dhall, G.I., Hazra, M.N., Kodkany, B.S., Lalitha, K., Logambal, A., Monchanda, P., Nanda, U.K. and RaiChoudhury, G. (1995) Return of fertility following discontinuation of Norplant-II subdermal implants. Contraception, 51, 237-242.
17. Chikamata, D.M. and Miller, S. (2002) Health services at the clinic level and implantable contraceptives for women. Contraception, 65, 97-106.
18. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet, 347, 1713-1727.
19. Coutinho, E.M., De Souza, J.C., Athayde, C., Barbosa, I.C., Alvarez, F., Brache, V., Gu, Z.P., Emuveyan, E.E., Adekunle, A.O., Devoto, L. et al. (1996) Multicentre clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate, Uniplant. Contraception, 53, 121-125.
20. Croxatto, H.B. (2002a) Progestin implants for female contraception. Contraception, 65, 15-19.
21. Croxatto, H.B. (2002b) Mechanisms that explain the contraceptive action of progestin implants for women. Contraception, 65, 21-27.
22. Croxatto, H.B. and Mäkäräinen, L. (1998) The pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception, 58, 91S-97S.
23. Croxatto, H.B., Diaz, S., Vera, R., Etchart, M. and Atria, P. (1969) Fertility control in women with a progestogen released in micro quantities from subcutaneous capsules. Am. J. Obstet. Gynecol., 105, 1135-1138.
24. Croxatto, H.B., Diaz, S., Pavez, M., Miranda, P. and Brandeis, A. (1982) Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants. Acta Endocrinol., 101, 307-311.
25. Croxatto, H.B., Diaz, S., Salvatierra, A.M., Morales, P., Epensberger, C. and Brandeis, A. (1987) Treatment with Norplant® subdermal implants inhibits sperm penetration through cervical mucus in vitro. Contraception, 36, 193-201.
26. Croxatto, H.B., Urbancsek, J., Massai, R., Coelingh Bennink, H. and van Beek, A. (1999) A multicentre efficacy and safety study of the single contraceptive implant Implanon. Hum. Reprod., 14, 976-981.
27. Curtis, K.M. (2002) Safety of implantable contraceptives for women: data from observational studies. Contraception, 65, 85-96.
28. d'Arcangues, C. (2000) Management of vaginal bleeding irregularities induced by progestin-only contraception. Hum. Reprod., 15 (Suppl. 3), 24-29.
29. Diaz, S. (2002) Breast-feeding and concurrent use of contraceptive implants. Contraception, 65, 39-46.
30. Diaz, S., Pavez, M., Miranda, P., Robertson, D.N., Sivin, I. and Croxatto, H.B. (1982) A five-year clinical trial of levonorgestrel silastic implants (Norplant™). Contraception, 25, 447-456.
31. Diaz, S., Pavez, M., Miranda, P., Johansson, E.D. and Croxatto, H.B. (1987a) Long-term follow up of women treated with Norplant implants. Contraception, 35, 551-567.
32. Diaz, S., Pavez, M., Cardenas, H. and Croxatto, H.B. (1987b) Recovery of fertility and outcome of planned pregnancies after the removal of Norplant subdermal implants or Copper-T IUDs. Contraception, 35, 569-579.
33. Diaz, S., Schiappacasse, V., Pavez, M., Zepeda, A., Moo-Young, A.J., Brandeis, A., Lähteenmäki, P. and Croxatto, H.B. (1995) Clinical trial with Nestorone subdermal contraceptive implants. Contraception, 51, 33-38.
34. Dorflinger, L.J. (2002) Metabolic effects of implantable steroid contraceptives for women. Contraception, 65, 47-62.
35. Egberg, N., van Beek, A., Gunnervik, C., Hulkko, S., Hirvonen, E., Larsson-Cohn, U. and Coeling Bennink, H. (1998) Effects on the hemostatic system and liver function in relation to Implanon and Norplant. A prospective randomized clinical trial. Contraception, 58, 93-98.
36. Ethiopia Ministry of Health (2001) An evaluation of Norplant® insertion and removal services in Ethiopia. Federal Democratic Republic of Ethiopia, Ministry of Health, Addis Ababa.
37. Fan, H.-M. and Han, L.-H. (1999) A multicentre clinical comparative study of domestically produced implant contraceptive No. I and No. II with Norplant (Three year follow-up). J. Reprod. Med., 8 (Suppl. 1), 47-52.
38. Faúndes, A., Tejeda, A.S., Brache, V. and Alvarez, F. (1987) Subjective perception of bleeding and serum ferritin concentrations in long term users of Norplant. Contraception, 35, 189-196.
39. Faúndes, A., Brache, V. and Alvarez, F. (1995) Functional life-span of the dominant follicle in pharmacologically induced anovulatory cycles. Hum. Reprod., 11, 114-116.
40. Fraser, I.S., Tiitinen, A., Affandi, B., Brache, V., Croxatto, H.B., Diaz, S., Ginsburg, J., Gu, S., Holma, P., Johansson, E. et al. (1998) Norplant consensus statement and background review. Contraception, 57, 1-9.
41. Fraser, I.S., Weisberg, E., Minehan, E. and Johansson, E.D. (2000) A detailed analysis of menstrual blood loss in women using Norplant® and Nestorone® progestogen-only contraceptive implants or vaginal rings. Contraception, 61, 241-251.
42. French, R.S., Cowan, F.M., Mansour, D.J., Morris, S., Procter, T., Hughes, D., Robinson, A. and Guillebaud, J. (2000) Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. Health. Technol. Assess., 4 (7), 109 pp.
43. Glasier, A. (2002) Implantable contraceptives for women: effectiveness, discontinuation rates, return of fertility and outcome of pregnancies. Contraception, 65, 29-37.
44. Gu, S.J., Du, M.K., Zhang, L.D., Liu, Y.L., Wang, S.H. and Sivin, I. (1994) A 5-year evaluation of NORPLANT contraceptive implants in China. Obstet. Gynecol., 83, 673-678.
45. Gu, S., Sivin, I., Du, M., Zhang, L., Ying, L., Meng, F., Wu, S., Wang, P., Gao, Y. and He, X. (1995) Effectiveness of Norplant implants through seven years: a large scale study in China. Contraception, 52, 99-103.
46. Hanhart, J. (1993) Women's views on Norplant: a study from Lombok, Indonesia. In: Mintzes, B., Hardon, A. and Hanhart, J. (eds), Norplant: under her skin. Eburon, Delft, pp. 27-46.
47. Hardee, K., Kjuda, B., Kamal, G.M., Shafiur Rahman, A.P. and McMahan, J. (1994) Contraceptive implant users and their access to removal services in Bangladesh. Int. Fam. Plann. Persp., 20, 59-65.
48. Hickey, M. and d'Arcangues, C. (2002) Vaginal bleeding disturbances and implantable contraceptives. Contraception, 65, 75-84.
49. Huber, J. (1998) Pharmacokinetics of Implanon: an integrated analysis. Contraception, 58, 85S-90S.
50. International Collaborative Post-marketing Surveillance of Norplant (2001a) Post-marketing Surveillance of Norplant® contraceptive implants: I. Contraceptive efficacy and reproductive health. Contraception, 63, 167-186.
51. International Collaborative Post-marketing Surveillance of Norplant (2001b) Post-marketing Surveillance of Norplant® contraceptive implants: II. Non-reproductive health. Contraception, 63, 187-209.
52. International Organization for Standardization (1997) Biological evaluation of medical devices. ISO 10993, International Organization for Standardization, Geneva.
53. Jordan, A. (2002) Toxicology of progestogens of implantable contraceptives for women. Contraception, 65, 3-8.
54. Klavon, S.L. and Grubb, G.S. (1990) Insertion site complications during the first year of Norplant use. Contraception, 41, 27-37.
55. Kuiper, H., Miller, S., Martinez, E., Loeb, L. and Darney, P. (1997) Urban adolescent females' views on the implant and contraceptive decision-making: a double paradox. Fam. Plann. Persp., 29, 167-172.
56. Mascarenhas, L. (1998) Insertion and removal of Implanon. Contraception, 58, 79S-83S.
57. Mascarenhas, L., van Beek, A., Bennink, H.C. and Newton, J. (1998) Twenty-four month comparison of apolipoproteins A-1, A-II and B in contraceptive implant users (Norplant and Implanon) in Birmingham, United Kingdom [published erratum appears in Contraception, 58, following 389]. Contraception, 58, 215-219.
58. Massai, R., Diaz, S., Quinteros, E., Reyes, V., Herreros, C., Zepeda, A., Croxatto, H. and Moo-Young, A. (2001) Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. Contraception, 64, 369-376.
59. Meirik, O., Farley, T.M.M. and Sivin, I. for the International Collaborative Post-marketing Surveillance of Norplant (2001) Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization. Obstet. Gynecol., 97, 539-547.
60. Nilsson, C.G. and Holma, P. (1981) Menstrual blood loss with contraceptive subdermal levonorgestrel implants. Fertil. Steril., 35, 304-306.
61. Odlind, V., Lithell, H., Selinus, I. and Vesby, B. (1984) Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST-1435. Upssala J. Med Sci., 89, 151-158.
62. Ortayli, N. (2002) Users' perspectives on implantable contraceptives for women. Contraception, 65, 107-111.
63. Petitti, D.B. and Shapiro, S. (1989) Strategies for post-registration surveillance of contraceptive steroids. In: Michal, F. (ed.), Safety Requirements for Contraceptive Steroids. Cambridge University Press, Cambridge, pp. 325-347.
64. Petitti, D.B., Piaggio, G., Mehta, S., Cravioto, M.C. and Meirik, O. (2000) Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet. Gynecol., 95, 736-744.
65. Rogers, P. and Salamonsen, L. (eds) (2000) Steroids and endometrial breakthrough bleeding. Hum. Reprod., 15 (Suppl. 3), 207 pp.
66. Sangi-Haghpeykar, H., Frank, M.L., Leonard, L. and Poindexter, A.N. (2000) A qualitative study of perceptions, attitudes and experiences of long-term levonorgestrel implant users. Women & Health, 30, 93-108.
67. Shastri, P.V. (2002) Toxicology of polymers of implantable contraceptives for women. Contraception, 65, 9-13.
68. Shen, Q., Lin, D., Jiang, X., Li, H. and Zhang, Z. (1994) Blood pressure changes and hormonal contraceptives. Contraception, 50, 131-141.
69. Simmons, R., Hall, P., Diaz, J., Diaz, M., Fajans, P. and Satia, J. (1997) The strategic approach to contraceptive introduction. Stud. Fam. Plann., 28, 79-94.
70. Singh, K. and Ratnam, S.S. (1997) A comparison of the clinical performance, contraceptive efficacy, reversibility and acceptability of Norplant implants and Ortho Gynae T380 intrauterine copper contraceptive device. Adv. Contracept., 13, 385-393.
71. Sivin, I. (1983) Clinical effects of Norplant subdermal implants for contraception. In: Mishell, D.R., Jr (ed.), Long-acting steroid contraception. New York, Raven Press, pp. 89-116.
72. Sivin, I. (1988) International experience with NORPLANT and NORPLANT-2 contraceptives. Stud Fam. Plann., 19, 81-94.
73. Sivin, I. (1995) Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System [letter]. Obstet. Gynecol., 86, 318-320.
74. Sivin, I. (1998) Data and analysis from Population Council studies. In: Harrison, P.F. and Rosenfield, A. (eds), Contraceptive Research, Introduction, and Use. Lessons from Norplant. Institute of Medicine. National Academy Press, Washington, DC, pp. 63-67.
75. Sivin, I. and Moo-Young, A. (2002) Recent developments in contraceptive implants at the Population Council. Contraception, 65, 113-119.
76. Sivin, I., Diaz, S., Holma, P., Alvarez-Sanchez, F. and Robertson, D.N. (1983a) A four-year clinical study of NORPLANT implants. Stud. Fam. Plann., 14, 184-191.
77. Sivin, I., Sanchez, F.A., Diaz, S., Holma, P., Coutinho, E., McDonald, O., Robertson, D.N. and Stern, J. (1983b) Three-year experience with NORPLANT subdermal contraception. Fertil. Steril., 39, 799-808.
78. Sivin, I., Stern, J., Diaz, S., Pavez, M., Alvarez, F., Brache, V., Mishell, D.R., Jr, Lacarra, M., McCarthy, T. and Holma, P. (1992) Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Am. J. Obstet. Gynecol., 166, 1208-1213.
79. Sivin, I., Läteenmäki, P., Mishell, D.R., Alvarez, F., Diaz, S., Ranta, S., Grozinger, C., Lacarra, M., Brache, V., Pavez, M. et al. (1997) First week drug concentrations in women with levonorgestrel rod or Norplant® capsule implants. Contraception, 56, 317-321.
80. Sivin, I., Campodónico, I., Kiriwat, O., Holma, P., Diaz, S., Wan, L., Biswas, A., Viegas, O., el din Abdallah, K., Anant, M.P. et al. (1998a) The performance of levonorgestrel rod and Norplant® contraceptive implants: a 5-year randomized study. Hum. Reprod., 13, 3371-3378.
81. Sivin, I., Mishell, D.R., Jr, Darney, P., Wan, L. and Christ, M. (1998b) Levonorgestrel capsule implant in the United States: a 5-year study. Obstet. Gynecol., 92, 337-344.
82. Suherman, S. K., Affandi, B. and Korver, T. (1999) The effects of Implanon on lipid metabolism in comparison with Norplant. Contraception, 60, 281-287.
83. Task Force for Epidemiological Research on Reproductive Health, United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (1998) Effects of contraceptives on hemoglobin and ferritin. Contraception, 58, 262-273.
84. Task Force on Long-Acting Systemic Agents for Fertility Regulation, United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (1999) Study of the effects of the implantable contraceptive Norplant on lipid and lipoprotein metabolism. Contraception, 59, 31-45.
85. Trussell, J., Leveque, J.A., Koenig, J.D., London, R., Borden, S., Henneberry, J., LaGuardia, K.D., Stewart, F., Wilson, T.G. and Wysocki, S. (1995) The economic value of contraception: a comparison of 15 methods. Am. J. Public Health, 58, 494-503.
86. Tseng, L.H., Lee, T.Y., Yang, Y.S., Ko, T.M. and Chuang, S.M. (1996) Norplant subdermal contraceptive system: experience in Taiwan. Contraception, 53, 177-180.
87. Urbancsek, J. (1998) An integrated analysis of non-menstrual adverse events with Implanon. Contraception, 58, 109S-115S.
88. Vandenbroucke, J.P., Rosing, J., Bloemenkamp, K.W., Middeldorp, S., Helmerhorst, F.M., Bouma, B.N. and Rosendaal, F.R. (2001) Oral contraceptives and the risk of venous thrombosis. N. Engl. J. Med., 344, 1527-1535.
89. Westhoff, C., Truman, C., Kalmuss, D., Cushman, L., Rulin, M., Heartwell, S. and Davidson, A. (1998) Depressive symptoms and Norplant contraceptive implants. Contraception, 57, 241-245.
90. Widyantoro, N. (1994) The story of Norplant implants in Indonesia. Reprod. Health Matters, 2(3), 20-29.
91. World Health Organization (1993) Depot-medroxyprogesterone acetate (DMPA) and cancer: Memorandum from a WHO meeting. Bull. WHO, 71, 669-673.
92. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1998) Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: results of an international multicenter case-control study. Contraception, 57, 315-324.
93. Wysowski, D.K. and Green, L. (1995) Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System. Obstet. Gynecol., 85, 538-542.
94. Zimmerman, M., Haffey, J., Crane, E., Szumowski, D., Alvarez, F., Bhiromrut, P., Brache, V., Lubis, F., Salah, M. and Shaaban, M. (1990) Assessing the acceptability of Norplant® implants in four countries: findings from focus group research. Stud. Fam. Plann., 21, 92-103.